Recursion Pharmaceuticals clinical trials we track

Check company identity source

Phase 2 / 3 1 trial

Phase 2 3 trials

TrialDrugs studiedStatusPrimary completion
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994NCT05085561REC-994Completed2025-06-30Actual
The Clostridioides Difficile Trial of REC-3964NCT06536465REC-3964Terminated2025-05-06Actual
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC MutationNCT06005974REC-4881Terminated2025-02-24Actual

Phase 1 / 2 2 trials

TrialDrugs studiedStatusPrimary completion
REC-7735 in Participants With Solid TumorsNCT07819136REC-7735Recruiting2031-01Estimated
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerNCT06678659REC-1245Recruiting2029-07Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

NCT05085561 · Recursion Pharmaceuticals Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence and severity of adverse events (AEs) Time frame: Up to 24 months. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Description: A TEAE was the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. TEAES which include treatment related TEAEs, serious TEAEs, treatment-related serious TEAEs, TEAEs leading to treatment discontinuation, and treatment-related TEAEs leading to treatment discontinuation are reported. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section Time frame: Up to a maximum of 1201 days.

Check registry source

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate the safety and tolerability of REC-4881 Measure: To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR). After: Measure: Number of Participants with Dose Limiting Toxicities Measure: Objective Response Rate.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 60 participants (planned). After: 18 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jan 2027. After: 24 Feb 2025.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source